The goal of the Zyprexa Relprevv Patient Care Program is to mitigate the risk of negative outcomes associated with Zyprexa Relprevv post-injection delirium/sedation syndrome (PDSS).
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Any patients receiving Zyprexa Relprevv enrolled in Zyprexa Relprevv Patient Care Program
Exclusion Criteria:
* Any patient not receiving Zyprexa Relprevv
Primary outcome measure(s)
Incidence per injection and per patient of post-injection delirium/sedation syndrome (PDSS) events — Baseline to end of study
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.